Chronic Inflammatory Demyelinating Polyneuropathy

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) is a neurological disorder characterized by progressive weakness and impaired sensory function in the arms and legs.

Featured Video

European Academy of Neurology (EAN) and Peripheral Nerve Society (PNS) Guideline on diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy: Report of a joint Task Force—Second Revision

CIDP

Watch Dr. Peter Van den Bergh, lead author, take you through the highlights of the guideline.

Videos about CIDP

VIEW ALL VIDEOS

Clinical Studies for the Treatment of CIDP with Immunoglobulin

Claudia Sommer, MD

University of Würzburg, Würzburg, Germany

9:35 MIN

CIDP
MMN

Discover the results of two recent clinical studies of IVIg treatments for CIDP.

DOWNLOAD PDF

20% Subcutaneous Immunoglobulin for Maintenance Treatment in Chronic Inflammatory Demyelinating Polyneuropathy (PATH): a Randomized, Double-blind, Placebo-controlled, Phase 3 Trial

Vera Bril, BSc, FRCPC, MD

University of Toronto,Toronto, Canada

15:31 MIN

CIDP

Learn about the PATH study results and SCIG (subcutaneous immunoglobulin) treatment in CIDP

DOWNLOAD PDF

CIDP Assessment Tools: Grip Strength

Jeffrey A. Allen, MD

University of Minnesota

01:52 MIN

CIDP

Listen to a discussion about Discussing tools that are commonly used to measure grip strength in CIDP

Wear-Off in IVIG and What it Means in Clinical Practice

Jeffrey A. Allen, MD
Carol L. Koski, MD
Thomas Harbo, MD

16:21 MIN

CIDP

Learn about wear-off effects in patients with CIDP, the tools available to monitor them, and the methods to combat them and tailor treatment to the patient.

SELECT A CHAPTER TO VIEW

Introduction

Introduction to wear-off effects

Monitoring wear-off effects

Combating wear-off effects

Conclusion

NOW PLAYING

9:35

Clinical Studies for the Treatment of CIDP with Immunoglobulin

Discover the results of two recent clinical studies of IVIg treatments for CIDP.

NOW PLAYING

15:31

20% Subcutaneous Immunoglobulin for Maintenance Treatment in Chronic Inflammatory Demyelinating Poly...

Learn about the PATH study results and SCIG (subcutaneous immunoglobulin) treatment in CIDP

NOW PLAYING

01:52

CIDP Assessment Tools: Grip Strength

Listen to a discussion about Discussing tools that are commonly used to measure grip strength in CIDP

NOW PLAYING

16:21

Wear-Off in IVIG and What it Means in Clinical Practice

Learn about wear-off effects in patients with CIDP, the tools available to monitor them, and the methods to combat them and tailor treatment to the patient.

Our Experts on CIDP

VIEW ALL EXPERTS

Michael Lunn, PhD

National Hospital for Neurology and Neurosurgery, Queen Square, London

Michael Lunn, PhD

National Hospital for Neurology and Neurosurgery, Queen Square, London

CIDP

Dr Michael Lunn is a Consultant Neurologist, Clinical Lead in Neuroimmunology and Honorary Senior Lecturer at the National Hospital for Neurology and Neurosurgery.

Mel Berger, MD, PhD

Medical Research Strategy, CSL Behring

Mel Berger, MD, PhD

Medical Research Strategy, CSL Behring

CIDP

Mel Berger is a Senior Director, Medical Research Strategy at CSL and Adjunct Professor of Pediatrics and Pathology, Case Western Reserve University. He earned his undergraduate, medical and PhD (in Biochemistry) degrees at Case Western Reserve University in Cleveland.

Thomas Harbo, MD, PhD

Aarhus University Hospital in Aarhus, Denmark

Thomas Harbo, MD, PhD

Aarhus University Hospital in Aarhus, Denmark

CIDP
GBS

Dr. Harbo is a neuromuscular specialist at Aarhus University Hospital in Aarhus, Denmark, a certified Centre of Excellence by the GBS|CIDP Foundation International.

Nabil Moumane, MD

Medical Affairs and Pharmacology, CSL Behring